<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2585">
  <stage>Registered</stage>
  <submitdate>24/11/2009</submitdate>
  <approvaldate>24/11/2009</approvaldate>
  <nctid>NCT01018771</nctid>
  <trial_identification>
    <studytitle>Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion</studytitle>
    <scientifictitle>A Prospective, Randomised Study Comparing the Use of Actifuse (Trademark) Advanced Bone Matrix (ABX) Synthetic Bone Substitute With INFUSE (Trademark) on Fusion in Patients Requiring Posterolateral Instrumented Lumbar Fusion</scientifictitle>
    <utrn />
    <trialacronym>APPRAISET2</trialacronym>
    <secondaryid>ACTRN12609000548235</secondaryid>
    <secondaryid>CIP0803PLF</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Degenerative Disc Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Actifuse ABX
Treatment: surgery - INFUSE, plus Mastergraft granules

Experimental: Actifuse ABX - Actifuse ABX bone substitute

Active Comparator: INFUSE, plus Mastergraft granules - 


Treatment: surgery: Actifuse ABX
bone graft to be used in posterolateral instrumented lumbar fusion

Treatment: surgery: INFUSE, plus Mastergraft granules
bone graft to be used in posterolateral instrumented lumbar fusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fusion, defined as evidence of bridging trabecular bone present at 1 year</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in the following clinical outcomes measurements: Pain/Disability as measured by Oswestry Lower Back Pain Questionnaire; Quality of Life as measured by Short Form Health Survey (SF36)and Neurological Status</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have degenerative disc disease of the lumbar spine as indicated by back pain of
             discogenic/degenerative origin with or without leg pain and has one or more of the
             following conditions as documented by Plain X-Rays, CT Scan or MRI Scan:

               -  Modic changes.

               -  High intensity changes in the annulus.

               -  Loss of disc height.

               -  Decreased hydration of the disc.

               -  Canal stenosis with or without Spondylotic slip.

               -  Gross facet joint changes requiring fusion for treatment.

               -  Have documented annular pathology by other means. (e.g. with discography).

          -  Have a preoperative Oswestry Back Disability Score of 30 or more.

          -  Aged 18 to 75 years and skeletally mature at time of surgery.

          -  Have not responded to non-operative treatment (e.g. bed rest, physical therapy,
             medications and/or spinal injections) for a period of six months.

          -  If of childbearing potential, patient is non-pregnant, non-nursing and agrees not to
             become pregnant for one year following surgery.

          -  Is will to and able to comply with the study plan and able to understand and sign the
             Patient Informed Consent Form.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Has had previous failed attempts at fusion surgery at the involved level(s).

          -  Has a diagnosis of spinal infection tumour or trauma.

          -  Requires surgery at more than two (2) levels.

          -  Has osteoporosis (excluding osteopenia) as evidenced on plain X-rays, CT Scans (or
             DEXA scan in cases of doubt).

          -  Is pregnant.

          -  Is an alcohol and/or drug abuser as defined by currently undergoing treatment for
             alcohol and/or drug abuse.

          -  Has received drugs that may interfere with bone metabolism within two weeks prior to
             the planned surgery date (e.g. steroids or methotrexate) excluding routine
             perioperative, non-steroidal anti-inflammatory drugs.

          -  Has a history of autoimmune disease.

          -  Has a history of exposure to injectable collagen implants.

          -  Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or
             gamma globulins) or collagen.

          -  Has received treatment with an investigational therapy (device and/or pharmaceutical)
             within 30 days prior to surgery or such treatment is planned during the 24 months
             following surgery.

          -  Has received any previous exposure to any/all BMPs of either human or animal
             extraction.

          -  Has a history of allergy to bovine products or a history of anaphylaxis.

          -  Has a history of any endocrine or metabolic disorder known to affect osteogenesis
             (e.g. Paget's disease, renal oseodystrophy, Ehlos-Danlos syndrome or Osteogenesis
             Imperfecta).

          -  Has any disease that would preclude accurate clinical evaluation (e.g. neuromuscular
             disease etc).

          -  Has a primary diagnosis of a spinal disorder other than degenerative disc disease or
             other conditions as set out in "Inclusions" above at the involved level(s).

          -  Has a condition that requires postoperative medications that interfere with fusion,
             such as steroids or prolonged use of non-steroidal anti-inflammatory drugs, excluding
             routine perioperative, non-steroidal anti-inflammatory drugs. This does not include
             low dose aspirin for prophylactic anticoagulation.

          -  Has overt or active bacterial infection, local or systemic and/or a potential for
             bacteremia.

          -  Has presence of active malignancy or prior history of malignancy (except for basal
             cell carcinoma of the skin).

          -  Has a documented metal allergy or intolerance to titanium alloy or
             cobalt-chrome-molybdenum alloy.

          -  Who, in the opinion of the Principal Investigator or Co-Investigators, is
             intellectually unable to co-operate with the study.

          -  Has chronic or acute renal and/or hepatic failure or prior history of renal or hepatic
             disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Moloney &amp; Associates - Wollongong</hospital>
    <postcode>NSW2522 - Wollongong</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Baxter Healthcare Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Apatech, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective randomised study.

      Primary objective: Evaluation of success rates of Actifuse ABX and INFUSE in achieving bone
      fusion.

      Secondary objectives: Assess clinical outcome measurements.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01018771</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Huub Kruewel, Ph.D</name>
      <address>Director, Medical Affairs</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>